A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Treatment with the highest dose of investigational injectable amycretin -- a unimolecular GLP-1 and amylin receptor agonist -- yielded a 22% weight loss after 36 weeks in a phase Ib/IIa trial, said ...
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
Medpage Today on MSN6d
No Clear Winner in SGLT2 Showdown for Cardiovascular Disease"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback